Dipal Doshi, Chief Executive Officer of Entrada Therapeutics, has been appointed to the Board of Directors of āshibio, a privately held, clinical-stage biotechnology company. āshibio is developing novel therapeutics for bone and connective tissue disorders, including a potential treatment for fibrodysplasia ossificans progressiva (FOP).
Mr. Doshi's appointment was announced by āshibio on September 17, 2025, following its exit from stealth mode in June 2024 with $40 million in seed and Series A financing. Pankaj Bhargava, CEO of āshibio, highlighted Mr. Doshi's significant experience in setting strategy and driving operational and commercial growth of biopharmaceutical companies.
Mr. Doshi's track record includes advancing Entrada's pipeline, completing multiple private financings, leading its IPO in 2021, and executing a transformational business development collaboration. His operating and fundraising experience is expected to be valuable for āshibio's growth and further enhances his standing in the biotech sector.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.